Coronavirus

"Keep the vaccination conversation going this year, even though your patients, and probably you, too, have grown tired of the issues and your team is worn out."

RSV is comparable to influenza every year in the severity of infection among older adults. Drs Bill Schaffner and Chuck Vega say both patients and clinicians will need education this season.

Findings from a recent study show a broad spectrum of possible clinical manifestations of IRD following SARS-CoV-2 infection or COVID-19 vaccination.

The expanded labeling for the antiviral against COVID-19 indicates no dose adjustment is required for persons across all stages of liver disease.

A large study of hospitalized children with SARS-CoV-2 infection found that disease severity varied by age over the course of the COVID-19 pandemic.

Well-known ID specialist Bill Schaffner, MD, and active primary care educator Chuck Vega, MD, offer thoughts on how to get shots into arms in the 2023-2024 respiratory virus season.

Patients hospitalized with COVID-19 were 2-times more likely to develop persistent hypertension than their influenza counterparts, according to results.

Respiratory virus season 2023-2024 will likely be a "transition year," according to family physician Chuck Vega, MD and ID specialist Bill Schaffner, MD. Here's why.

Eris, or EG5, is of Omicron lineage and accounts for ~17% of reported COVID-19 cases; mRNA vaccine producers are confident in the new shots to protect against it.

A daily dose of clinical news on Patient Care you may have missed.

Findings from a new study show the long-term benefits of COVID-19 vaccination to reduce inflammation after a breakthrough infection, say researchers.

CDC immunization recommendations for influenza, COVID-19, and RSV from the updated 2023 schedules are summarized in this Guideline Topline.

A daily dose of clinical news on Patient Care you may have missed.

The only head-to-head trial of mRNA COVID-19 vaccine safety in older adults finds one has a slight edge over the other, which might just be enough for some patients.

The arrival of COVID-19 vaccines challenged many people for the first time to understand the actual public health role of vaccination. With the RSV shots, it may be round 2.

The triple assay can identify and differentiate influenza, COVID-19, and respiratory syncytial virus in approximately 2 hours and is already in use.

The real-world analysis measured the benefit of primary vaccination and of a booster and found the latter dependent upon local disease incidence and risk for severe disease.

For the 25-30 million uninsured adults in the US, the program, which will end in December 2024, will ensure access to protection from the virus for another year.

In the post COVID-19 pandemic health care emergency era, private and public insurance entities will continue full coverage of the shots - but what about the uninsured?

Listen to 2 obesity experts discuss the impact of the COVID-19 pandemic on obesity-related type 2 diabetes.

The FDA's VRBPAC members were unanimous in their recommendation that the 2023-24 COVID vaccines reflect the dominant strain in circulation, XBB.

The FDA advisory committee will review all current surveillance data and recommend which strain/s to include in updated COVID-19 vaccines for the 2023-2024 vaccination campaign.

Your daily dose of clinical news you may have missed.

More research is needed to determine whether metformin is also effective in patients with lower body mass index or with previous infection, said researchers.

Need more talking points to help patients grasp the importance of the bivalent COVID-19 vaccine? The answers to these 3 questions should help.

Primary care clinicians will often be the first challenged to recognize neurologic sequelae of COVID-19; here's how to maximize short visits to assess long COVID.

Coauthor of a new multidisciplinary guidance statement on assessment of neurologic sequelae of long COVID highlights a consensus on steps to rule the condition out.

A Feinberg School of Medicine physiatrist with long experience assessing long COVID talks specifically about common neurologic sequelae of the infection.

Researchers found a total of 12 symptoms that contributed to the long COVID scoring system.

The FDA approved Paxlovid™ for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe disease.